Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PTPRC | P08575 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2186647 | 1.00 | KDM4E (0.33) | KDM4EMEN1ALDH1A1LMNABCHE | |
| SCHEMBL10512958 | 0.83 | PTPRC (0.33) | PTPRC | |
| SCHEMBL30816755 | 0.77 | MEN1 (0.33) | KDM4EMEN1ALDH1A1LMNABCHE | |
| SCHEMBL379612 | 0.74 | TRPA1 (0.33) | TRPA1 | |
| SCHEMBL379614 | 0.74 | TRPA1 (0.33) | TRPA1 | |
| SCHEMBL568780 | 0.74 | MEN1 (0.46) | KDM4EMEN1ALDH1A1LMNABCHE | |
| SCHEMBL504078 | 0.74 | MEN1 (0.46) | KDM4EMEN1ALDH1A1LMNABCHE | |
| Fluoride SCHEMBL28557472 | 0.72 | TRPA1 (0.32) | TRPA1 | |
| SCHEMBL9985286 | 0.71 | MEN1 (0.44) | KDM4EMEN1ALDH1A1LMNABCHE | |
| SCHEMBL9985289 | 0.71 | MEN1 (0.44) | KDM4EMEN1ALDH1A1LMNABCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024086781-A2 | METHODS AND SYSTEMS FOR CHARACTERIZING PHOSPHOSERINE-CONTAINING POLYPEPTIDES | Quantum-Si Incorporated (US) | 2024-04-25 | — | — | WO | claimed |
| WO-2024073442-A1 | METHODS FOR ISOLATING, DETECTING, AND QUANTIFYING INTERCELLULAR PROTEINS | FRED HUTCHINSON CANCER CENTER (US) | 2024-04-04 | — | — | WO | claimed |
| US-11938196-B2 | Modified viral particles for gene therapy | BOREA THERAPEUTICS S.R.L. (IT) | 2024-03-26 | — | — | US | claimed |
| US-20240016933-A1 | Methods of Anchoring or Reconstituting Active Molecules on Metabolically Labeled Cells | MASSACHUSETTS GEN HOSPITAL (US) | 2024-01-18 | — | — | US | claimed |
| US-20240002908-A1 | METHODS OF DETERMINING SURFACE GLYCAN DENSITY | MASSACHUSETTS GEN HOSPITAL (US) | 2024-01-04 | — | — | US | claimed |
| US-20230406839-A1 | Bifunctional Compounds And Methods Of Using The Same | THE GENERAL HOSPITAL CORPORATION | 2023-12-21 | — | — | US | claimed |
| WO-2023212656-A1 | BIOMATERIALS FOR IMPROVING BRAIN HEALING AFTER STROKE AND METHODS OF USING SAME | DUKE UNIVERSITY (US) | 2023-11-02 | — | — | WO | claimed |
| US-20230338578-A1 | MODIFIED VIRAL PARTICLES FOR GENE THERAPY | EUROPEAN MOLECULAR BIOLOGY LABORATORY (DE) | 2023-10-26 | — | — | US | claimed |
| WO-2023178422-A1 | LIPID BASED NANOPARTICLES FOR TARGETED GENE DELIVERY TO THE BRAIN | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2023-09-28 | — | — | WO | claimed |
| WO-2023178421-A1 | ANTIBODIES WITH ENGINEERED O-GLYCOSYLATION SEQUONS FOR SITE-SPECIFIC CONJUGATION | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2023-09-28 | — | — | WO | claimed |
| US-20120108499-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2012-05-03 | — | — | US | claimed |
| EP-2343285-A2 | Peptoid compounds | UNIVERSITY OF WOLLONGONG (AU) | 2011-07-13 | — | — | EP | claimed |
| US-20100167995-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2010-07-01 | — | — | US | claimed |
| JP-4446736-B2 | — | — | 2010-04-07 | — | — | JP | claimed |
| EP-1412336-A4 | PEPTOID COMPOUNDS | UNIV WOLLONGONG (AU) | 2007-08-29 | — | — | EP | claimed |
| US-20070111927-A1 | Peptoid compounds | UNIVERSITY OF WOLLONGONG (AU) | 2007-05-17 | — | — | US | claimed |
| US-20050043509-A1 | Peptoid compounds | UNIVERSITY OF WOLLONGONG | 2005-02-24 | — | — | US | claimed |
| JP-2005504734-A | — | — | 2005-02-17 | — | — | JP | claimed |
| EP-1412336-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2004-04-28 | — | — | EP | claimed |
| WO-2003002545-A1 | PEPTOID COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2003-01-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108499-A1 | PEPTOID COMPOUNDS | VIP, FPR1, VIPR1 | KDM4E 4594/4885MEN1 3065/4885ALDH1A1 4540/4885 |
| US-20100167995-A1 | PEPTOID COMPOUNDS | VIP, FPR1, VIPR1 | KDM4E 4594/4885MEN1 3065/4885ALDH1A1 4540/4885 |
| US-20240016933-A1 | Methods of Anchoring or Reconstituting Active Molecules on Metabolically Labeled Cells | CD4, CD14, CD69 | KDM4E 4309/4885MEN1 3721/4885ALDH1A1 2659/4885 |
| US-20230338578-A1 | MODIFIED VIRAL PARTICLES FOR GENE THERAPY | HAVCR2, TMEM205, COPA | KDM4E 4208/4885MEN1 4445/4885ALDH1A1 2068/4885 |
| US-20070111927-A1 | Peptoid compounds | VIP, FPR1, VIPR1 | KDM4E 4594/4885MEN1 3065/4885ALDH1A1 4540/4885 |
| US-11938196-B2 | Modified viral particles for gene therapy | HAVCR2, TMEM205, COPA | KDM4E 4208/4885MEN1 4445/4885ALDH1A1 2068/4885 |
| US-20230406839-A1 | Bifunctional Compounds And Methods Of Using The Same | PAICS, PAPSS1, GNE | KDM4E 3714/4885MEN1 1168/4885ALDH1A1 1596/4885 |
| US-20050043509-A1 | Peptoid compounds | VIP, FPR1, VIPR1 | KDM4E 4594/4885MEN1 3065/4885ALDH1A1 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.